A second study from the same group found a higher mortality in hyperglycaemic patients without diabetes at 30 days.
This observation was validated in a second study from the same group published in the late 1990s [ 14].
A second study, drawn from the same database, found mobility has remained relatively constant over time in recent decades.
A second study, from Oxford Brookes University, produced similar evidence.
In a second study by the same multicenter group, 142 patients with advanced dysplasia were treated.
In a second study, though, the same procedure was used.
In a second study in the same journal, a team headed by Dr. Maarten L. Simoons of University Hospital Rotterdam, the Netherlands, observed no benefit at all from using abciximab alone.
In a second study, the researchers found the same was true for zebra finches.
In a second study, Grant and Gino provided the exact same scenario as in the first.
And on the same day, 10/30/14 again: A third study reports finding 60 genes.
